MGMT promotor methylation status is included in the WHO 2016 classification of gliomas to facilitate clinical decision making. Internationally different methods and different cut-off levels are used to define a tumor as methylated or unmethylated, thereby selecting partly different patient populations.In this survey we wish to find out which different methods are regularly used for clinic and the reason for selecting the specific method. The results are planned to be reported at the EANO meeting in October 2018 in Stockholm.
Thank you for your contribution!
Dr Annika Malmström, Prof Bjarne Winther Kristensen, Prof Peter Söderkvist and Prof Roger Henriksson representing the Scandinavian Neuro-Oncology Society